Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Healthcare sector has seen a modest bid since mid-July compared to the S&P 500, with a reach for perceived safety. Agilent Technologies is a leading supplier in the Life Sciences Tools and Services industry. Agilent's earnings and valuation outlooks are mixed, with weak near-term growth but potential for improvement in the future.

Agilent: Dips Into GARP Territory, Shares At A Crucial Spot On The Chart

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on Oct. 25, 2023, to all shareholders of record as of the close of business on Oct. 3, 2023. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laborator.

Agilent Announces Cash Dividend of 22.5 Cents Per Share

Agilent (A) collaborates with the National Cancer Centre Singapore to accelerate Asian-prevalent cancer research over the next two years.

Agilent (A) Boosts Genomic Profiling With New Collaboration

Exact Sciences

SANTA CLARA, Calif. & MADISON, Wis.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of Resolution Bioscience to Exact Sciences. Financial terms of the agreement were not disclosed and are not material to either party. “We are pleased that Exact Sciences is acquiring Resolution Bioscience,” said Sam Raha, senior vi.

Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced Philip Binns has been named president of the company's Life Sciences and Applied Markets Group (LSAG). Binns previously served as vice president and general manager of the Spectroscopy and Vacuum Solutions Division for LSAG. Binns replaces Jacob Thaysen who left the company effective today. “We're extremely pleased to have someone with Phil's knowledge, experience and proven leadership strengths heading u.

Agilent Names Philip Binns to Lead Life Sciences and Applied Markets Group

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a companion diagnostic (CDx) Class C IVDR certification for PD-L1 IHC 22C3 pharmDx, Code SK006. This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR). PD-L1 IHC 22C3 pharmDx, Code SK006, is indicated as an aid in identifying certain cancer patients for treat.

Agilent Receives European IVDR Certification for Companion Diagnostic Assay

Agilent Technologies' (A) third-quarter fiscal 2023 results reflect weakness in the LSAG segment and China market.

Agilent (A) Q3 Earnings Beat Estimates, Revenues Fall Y/Y

Disappointing guidance from lab-instruments maker Agilent overshadowed a strong fiscal-fourth-quarter report. Agilent cited "softer market conditions in China and continued global macroeconomic challenges.

Agilent Stock Is Falling. China Weakness Hurt Guidance.

Agilent Technologies Inc. A shares fell 2% premarket on Wednesday after the laboratory instrument maker late Tuesday trimmed its full-year revenue and earnings outlook, citing weakness in China. The company now expects full-year revenue in the range of $6.80 to $6.85 billion, down from $6.93 to $7.03 billion previously, and full-year adjusted earnings per share of $5.40 to $5.43, versus a previous forecast of $5.60 to $5.65.

Agilent stock falls after lab instrument maker trims full-year outlook on China weakness

Agilent Technologies, Inc. (NYSE:A ) Q3 2023 Earnings Conference Call August 15, 2023 4:30 PM ET Company Participants Parmeet Ahuja - IR Mike McMullen - President and CEO Robert McMahon - SVP and CFO Padraig McDonnell - President, Agilent CrossLab Group Sam Raha - President, Agilent Diagnostics & Genomics Group Jacob Thaysen - President, Agilent Life Science & Applied Markets Group Conference Call Participants Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Vijay Kumar - Evercore ISI Dan Leonard - Credit Suisse Brandon Couillard - Jefferies Puneet Souda - Leerink Partners Rachel Vatnsdal - JPMorgan Patrick Donnelly - Citi Derik De Bruin - Bank of America Josh Waldman - Cleveland Research Dan Brennan - TD Cowen Luke Sergott - Barclays Operator Ladies and gentlemen, welcome to the Agilent Technologies Q3 2023 Earnings Conference Call. My name is Bo and I will be coordinating your call today.

Agilent Technologies, Inc. (A) Q3 2023 Earnings Call Transcript

H&R Block

The Dow slid -360 points in today's trading session, -1.02%, while the Nasdaq was down -157 points, -1.14%.

Markets Remain Sold; H&R Block (HRB), Agilent (A) Beat

The headline numbers for Agilent (A) give insight into how the company performed in the quarter ended July 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Agilent (A) Reports Q3 Earnings: What Key Metrics Have to Say

Medical equipment maker Agilent Technologies cut annual profit and sales forecasts for a second straight quarter as demand stays soft in major market China due to a slow economic recovery.

Agilent Technologies cuts annual forecasts on China weakness

Cava Group, Inc.

Disney

Stride

The Walt Disney Company (NYSE:DIS) is being sued by Hollywood financer TSG Entertainment for allegedly withholding millions of dollars worth of film profits.  The suit, filed Tuesday in Los Angeles Superior Court, accuses Disney and 20th Century Fox of breaching contract by withholding as much as $40 million in profits and signing side agreements to boost its own streaming platform and share price, according to reports.

The Afterhours: Disney sued for withholding profits; Cava, Agilent and Stride report earnings

Agilent Technologies (NYSE:A) Inc announced after Tuesday's close that its third-quarter 2023 revenue slipped 2.7% year over year to $1.67 billion but edged past the consensus estimate of $1.66 billion.  The analytical and clinical laboratory technologies provider also recorded better-than-expected earnings per share (EPS) of $1.43, exceeding the consensus forecast by $0.07.

Agilent Technologies 3Q financial results beat estimates; guidance disappoints

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the third quarter ended July 31, 2023, a decrease of 2.7% compared to the third quarter of 2022 and a decrease of 2.3% on a core(1) basis. Third-quarter GAAP net income was $111 million, or $0.38 per share. This compares with $329 million, or $1.10 per share, in the third quarter of fiscal year 2022. Non-GAAP(2) net income was $422 million, or $1.43 per share during the quarter,.

Agilent Reports Third-Quarter Fiscal Year 2023 Financial Results

Agilent Technologies' (A) results for the fiscal third quarter are expected to reflect strength across the ACG and DGG segments. However, weakness in the LSAG segment is likely to be a concern.

Agilent Technologies (A) to Post Q3 Earnings: What's in Store?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that Ajit Divakaruni, Ph.D., has received the Agilent 2023 Early Career Professor Award. Dr. Divakaruni is an Assistant Professor in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). The 2023 award focused on contributions to developing live cell analytical tools to identify and measure novel critical quality attributes to advance biomanufacturing appl.

Agilent 2023 Early Career Professor Award Presented to Ajit Divakaruni

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced that Dr. Peter Neubauer has been selected to receive a prestigious Agilent Thought Leader Award. As Chair of Bioprocess Engineering at the Technical University of Berlin, Dr. Neubauer leads innovative research to identify new methods for more efficient bioprocess development, including genetic, cultivation, and analytical tools, with a particular focus on industrial-scale applications. Automation and high throug.

Agilent Announces Thought Leader Award to Peter Neubauer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today released its 2022 ESG report on the company's work supporting customers with their sustainability initiatives while advancing its own internal high-priority ESG programs, from reducing Scope 3 emissions in the value chain to cultivating a talented, diverse, and inclusive workforce. “Agilent is committed to our customers' success at every stage of their journey to bring great science to life,” said Agilent President.

Agilent's 2022 ESG Report Shows Progress Helping Customers Reach Their Sustainability Goals

RTX said some 200 engines will have to be removed from airline fleets for accelerated inspections.

RTX tumbles after disclosing engine manufacturing issue on some A320 planes

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2023 after the stock market closes on Tuesday, Aug. 15. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call will also be available on the website for 90 days. About.

Agilent to Announce Third-Quarter Fiscal Year 2023 Financial Results Aug. 15

Agilent Technologies share price is down from its 52-week high of $160, but its Q2 results and a forward P/E of 21 make it an attractive buy. The company has announced its 10th consecutive annual cash dividend and is appealing a decision on CRISPR gRNA patents, which could boost its share price. Agilent stock has a solid capital deployment program, with $4.4 billion worth of shares repurchased since 2015 and $1.6 billion distributed as dividends; it also announced a $2 billion buyback plan.

Agilent Technologies: Solid Operational Performance Paves The Way For The Future

Agilent Technologies, a $35 billion leader in global life sciences, is trading 30% below its all-time high and 20% down year-to-date, presenting a potential growth/value opportunity. Despite challenges with conversion rates and macro uncertainties, Agilent's focus on resilient areas like pharmaceuticals, aggressive R&D spending, and global presence makes it a compelling investment. The company is benefiting from tailwinds in MedTech, biotechnology, and life science tools, and anticipates a continued increase in recurring revenue or consumables over time.

Agilent Technologies - A Wealth Compounder 30% Below Its Highs

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has achieved certification as a Great Place to Work®. The recognition reflects Agilent's commitment to creating a positive work environment that fosters employee engagement, innovation, teamwork and professional growth. Agilent earned Great Place to Work certification in Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Hong Kong, India, Ireland, Italy, Japa.

News for Agilent Technologies Stock (A)